Anika Therapeutics (ANIK) Tops Q4 EPS by 9c

Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of $0.53, $0.09 better than the analyst estimate of $0.44. Revenue for the quarter came in at $29.4 million versus the consensus estimate of $29.85 million.

Guidance:

"Looking forward to 2018, the Company expects total revenue growth to be around the mid-single digit percentage range for the full year of 2018. Licensing, milestone and contract revenue is expected to be $5 million for the year."

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.

You May Also Be Interested In

• Netflix shares fall over 5% premarket on soft current-quarter revenue guidance
• Danaher (DHR) Tops Q3 EPS by 19c, Beats on Revenue; Offers FY26 EPS Guidance
• AT&T (T) Tops Q3 EPS by 5c; offers guidance